QNZ (EVP4593): Potent NF-κB Inhibitor for Inflammation and Neurodegeneration Research

Executive Summary: QNZ (EVP4593) is a small-molecule quinazoline derivative and potent inhibitor of NF-κB transcriptional activation, with an IC₅₀ of 11 nM in human Jurkat T cells and 7 nM for TNF-α inhibition under PMA/PHA stimulation (APExBIO, product page). It efficiently suppresses inflammation in cellular and animal models, reduces edema formation in a carrageenin-induced rat paw model, and exhibits beneficial effects in Drosophila Huntington’s disease models without detectable toxicity. The compound is insoluble in water but soluble in ethanol and DMSO, facilitating flexible experimental workflows. QNZ’s validated mechanism of action and reproducible benchmarks position it as a reference tool for NF-κB pathway research and related disease modeling (see contrast).

Biological Rationale

NF-κB is a central transcription factor regulating genes involved in inflammation, immunity, cell survival, and fibrosis. Its dysregulation underlies a range of pathologies, including chronic inflammation, certain cancers, and neurodegenerative diseases. In infectious models such as Staphylococcus aureus osteomyelitis, persistent NF-κB activation contributes to pathological fibrosis and impaired immune clearance (Yang et al., 2025). Therapeutic targeting of NF-κB signaling is thus a priority for dissecting disease mechanisms and evaluating antifibrotic or anti-inflammatory strategies. QNZ (EVP4593) was developed to provide high-specificity, nanomolar-level inhibition of NF-κB-driven transcriptional activation, enabling controlled experimental modulation of this pathway across various disease-relevant models (APExBIO).

Mechanism of Action of QNZ (EVP4593)

QNZ (EVP4593) is a synthetic quinazoline derivative identified via luciferase reporter gene assays for its potent NF-κB inhibitory properties. It blocks NF-κB transcriptional activation by preventing nuclear translocation and DNA binding of NF-κB subunits in response to pro-inflammatory stimuli such as PMA (phorbol 12-myristate 13-acetate), PHA (phytohemagglutinin), and TNF-α. In human Jurkat T cells, QNZ exhibits an IC₅₀ of 11 nM for NF-κB inhibition and 7 nM for TNF-α production suppression. This blockade attenuates expression of downstream inflammatory mediators and cytokines. QNZ also reduces store-operated calcium entry (SOC) influx at 300 nM in neuronal cultures, a process implicated in Huntington’s disease pathology. Its mechanism is specific to the NF-κB pathway, with minimal off-target effects at recommended concentrations (APExBIO).

Evidence & Benchmarks

• QNZ (EVP4593) inhibits PMA/PHA-induced NF-κB activation in human Jurkat T cells with an IC₅₀ of 11 nM (APExBIO).
• Suppresses TNF-α production in Jurkat cells at an IC₅₀ of 7 nM (APExBIO).
• Reduces edema in a rat carrageenin-induced paw model, confirming anti-inflammatory efficacy in vivo (APExBIO).
• Slows progressive motor decline in Drosophila Huntington’s disease transgenic models without detectable toxicity (APExBIO).
• Inhibits store-operated calcium entry (SOC) influx in neuronal cultures at 300 nM, relevant to neurodegenerative disease (APExBIO).
• Demonstrates robust pathway inhibition, supporting advanced studies of NF-κB-driven inflammation and fibrosis (Yang et al., 2025).

In comparison, previous summaries such as this article describe QNZ’s potency; here, we extend the discussion with current in vivo and translational benchmarks. For hands-on troubleshooting and protocols, see scenario-driven best practices, which focus on workflow optimization, while this article emphasizes mechanistic and translational evidence.

Applications, Limits & Misconceptions

QNZ (EVP4593) is primarily used to dissect NF-κB pathway contributions in inflammation, infection-driven fibrosis, and neurodegenerative diseases such as Huntington’s disease. It is valuable in both cell culture and animal models for preclinical research. The compound’s selectivity and low nanomolar potency enable precise pathway modulation. However, its utility is subject to caveats regarding solubility, long-term stability, and specificity outside of the NF-κB axis. For broader context on scenario-driven solutions and experimental design, this guide provides practical advice, while the present review clarifies performance boundaries and evidence strength.

Common Pitfalls or Misconceptions

• Not water-soluble: QNZ (EVP4593) is insoluble in water; attempting aqueous dissolution leads to precipitation and inconsistent dosing (APExBIO).
• Long-term solution storage: Stock solutions in DMSO or ethanol are not recommended for long-term storage; repeated freeze-thaw cycles reduce potency.
• Off-target effects at high concentrations: Doses above recommended nanomolar ranges may produce non-specific inhibition of other signaling pathways.
• Not a direct antimicrobial: QNZ does not exhibit direct bactericidal activity; its utility in infection models is modulation of host response, not pathogen clearance (Yang et al., 2025).
• Limited clinical evidence: QNZ is for research use only and has not been evaluated for clinical therapy in humans.

Workflow Integration & Parameters

For optimal solubility, QNZ (EVP4593) should be dissolved in ethanol (≥10.06 mg/mL with ultrasonic assistance) or DMSO (≥15.05 mg/mL). Warming to 37°C and using ultrasonic shaking further enhances dissolution. Use freshly prepared stock solutions, stored at -20°C, to maintain activity. In neuronal culture systems, a 300 nM working concentration attenuates SOC influx. In cell-based NF-κB assays, titrate within the 1–100 nM range to determine pathway specificity. Avoid long-term storage in solution and limit freeze-thaw cycles to retain compound potency (APExBIO).

Conclusion & Outlook

QNZ (EVP4593) is a high-potency, selective NF-κB inhibitor with defined anti-inflammatory and neuroprotective effects in validated models. Its robust, reproducible performance supports advanced research into NF-κB pathway modulation, fibrosis, and neurodegeneration. As research evolves, QNZ remains a reference tool for dissecting inflammatory signaling. For comprehensive product details and ordering, see the APExBIO QNZ (EVP4593) product page (SKU A4217).